Overall survival data are not yet mature , although at the time of this analysis , median overall survival was 3364 months ( 95 % CI 3134-not estimable ) for the panobinostat group and 3039 months ( 2687-not estimable ) for the placebo group ( HR 087 , 95 % CI 069-110 ; p = 026 ) .